PAR 0.00% 23.5¢ paradigm biopharmaceuticals limited..

Yes, but if a partner wants more data, we should produce it in a...

  1. 284 Posts.
    lightbulb Created with Sketch. 79
    Yes, but if a partner wants more data, we should produce it in a phase 3 trial and why not have a subset of subjects generate this…. now. I’m really happy to see these outcome measurements maintained, even if we are a durable pain and function drug in 2025.

    I understand the costs to monitor/apply for DMOAD and the monitoring required would be financially onerous (unless a partner is sitting and waiting to strike once 2mg dose is approved, trial design is re-worked and adrenal misnomer is addressed.) F@CK knows. As KP said, no one knows (except a few that think they do).

    It’s a piece of information I’ve been waiting for. This is a big moment.

    I wonder if DMOAD label can be attained in Aussie TGA provisional approval?

    I also wonder if a subset of phase 3 stage 2 trial subjects are outcome measured for DMOAD, whether that data can be used for accelerated approval, too.

    Donna, no doubt working on all this. She is a gun. What would we do without her?
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
(20min delay)
Last
23.5¢
Change
0.000(0.00%)
Mkt cap ! $82.20M
Open High Low Value Volume
23.5¢ 24.0¢ 23.0¢ $133.5K 564.6K

Buyers (Bids)

No. Vol. Price($)
3 108916 23.5¢
 

Sellers (Offers)

Price($) Vol. No.
24.0¢ 58538 2
View Market Depth
Last trade - 16.10pm 17/06/2024 (20 minute delay) ?
Last
23.5¢
  Change
0.000 ( 0.00 %)
Open High Low Volume
24.0¢ 24.0¢ 23.5¢ 80791
Last updated 15.54pm 17/06/2024 ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.